Seongkoo Kim
Overview
Explore the profile of Seongkoo Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
91
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee J, Jo S, Yoo J, Kim S, Chung N, Cho B
Blood Res
. 2024 Oct;
59(1):32.
PMID: 39414685
Essential thrombocytosis (ET) is a rare myeloproliferative disease in children, and there are few standard management guidelines. We herein report a case series of 10 pediatric patients with ET diagnosed...
2.
Sim S, Park S, Yoo J, Kim S, Lee J, Chung N, et al.
Ann Pediatr Endocrinol Metab
. 2024 Sep;
29(4):266-275.
PMID: 39231488
Purpose: Glycated hemoglobin (HbA1c) as a glycemic index may have limited value in pediatric patients with acute leukemia as they often present with anemia and/or pancytopenia. To address this issue,...
3.
Lee J, Kim H, Yoo J, Lee J, Ahn A, Cho H, et al.
Br J Haematol
. 2024 May;
205(4):1581-1589.
PMID: 38735735
Inherited bone marrow failure syndromes (IBMFS) pose significant diagnostic challenges due to overlapping symptoms and variable expressivity, despite evolving genomic insights. The study aimed to elucidate the genomic landscape among...
4.
Yoo J, Jo S, Ahn M, Kim S, Lee J, Kim M, et al.
Cancers (Basel)
. 2023 Aug;
15(15).
PMID: 37568679
We conducted a retrospective study on 51 pediatric patients with newly diagnosed chronic myeloid leukemia chronic phase or accelerated phase. The patients were classified into the IMA group (N =...
5.
Jo S, Yoo J, Kim S, Lee J, Im S, Cho B, et al.
Front Oncol
. 2023 Apr;
13:1122714.
PMID: 37035148
Most children with chronic myeloid leukemia (CML) present with the chronic phase (CML-CP) at diagnosis, exhibiting an excellent treatment response to contemporary tyrosine kinase inhibitors (TKIs). However, despite TKI therapy,...
6.
Jang W, Jo S, Yoo J, Kim S, Lee J, Jang P, et al.
Blood Res
. 2022 Dec;
57(4):256-263.
PMID: 36535640
Background: Allogeneic HSCT may improve survival in pediatric ALL patients who relapse. In this study, we analyzed the outcome and prognostic factors of 62 ALL patients (35 male, 56.5%) who...
7.
Yoo J, Ahn A, Lee J, Jo S, Kim S, Lee J, et al.
J Clin Med
. 2022 Nov;
11(21).
PMID: 36362526
The wide application of next-generation sequencing (NGS) technologies has led to the discovery of multiple genetic alterations in pediatric acute lymphoblastic leukemia (ALL). In this work, we aimed to investigate...
8.
Lee J, Kim Y, Ahn A, Lee J, Yoo J, Kim S, et al.
Front Oncol
. 2022 Oct;
12:957743.
PMID: 36185293
Measuring minimal residual disease (MRD) during treatment is valuable to identify acute lymphoblastic leukemia (ALL) patients who require intensified treatment to avert relapse. We performed the next-generation sequencing (NGS)-based immunoglobulin...
9.
Kim Y, Kim S, Lee J, Ahn A, Yoo J, Lee J, et al.
Front Pediatr
. 2022 Aug;
10:928136.
PMID: 35967571
Lifelong treatment of pediatric chronic myeloid leukemia (CML) patients with tyrosine kinase inhibitors (TKIs) can affect their growth and development. For these reasons, clinical trials have explored the feasibility of...
10.
Koh K, Han J, Choi H, Kang H, Lee J, Yoo K, et al.
Cancer Res Treat
. 2022 Aug;
55(1):279-290.
PMID: 35952715
Purpose: Renal tumors account for approximately 7% of all childhood cancers. These include Wilms tumor (WT), clear cell sarcoma of the kidney (CCSK), malignant rhabdoid tumor of the kidney (MRTK),...